ALS Ice Bucket Challenge Progress
  • Sign up
  • |
  • Login
  • |
  • Find local services
  • |
  • |


CReATe Consortium

The Clinical Research in ALS and related disorders for Therapeutic Develoment (CReATe) Consortium is a collaborative effort to foster the discovery and validation of biomarkers relevant to therapy development for people living with ALS and related disorders including frontotemporal dementia (FTD), primary lateral sclerosis (PLS), hereditary spastic paraplegia (HSP), and progressive muscular atrophy (PMA). CReATe is a Rare Diseases Clinical Research Consortium (RDCRC) that forms part of the National Institutes of Health (NIH) Rare Diseases Clinical Research Network.

In partnership with The ALS Association, CReATe is able to advance its goals through the release of an annual request for applications to fund biomarker pilot projects. CReATe also fosters biomarker development by making its substantial repository of biological samples available to the broader scientific community.

The ALS Association Commitment

The Association supports three areas through CReATe:


The overall goal of CReATe is advance the discovery and validation of biomarkers ALS relevant to therapy development for people living with ALS and related disorders. In addition, researchers aim to understand the relationship between clinical phenotype (observable traits) and underlying genotype (DNA sequence).

How CReATe advances the search for a treatment for ALS

Key Players

Michael Benatar, M.D., Ph.D., Director of CReATe, Professor of Neurology and Epidemiology and Public Health at the University of Miami in Miami.

The Consortium has sites at the following centers: University of Miami, Florida, University of Kansas Medical Center, University of California at San Diego, California Pacific Medical Center, University of Tübingen, Germany, University of Pennsylvania, The Ohio State University, University of Texas Southwestern, University of Texas Health Sciences Center San Antonio, University of Toronto, University of Iowa, University of Virginia, Wake Forest University and Cleveland Clinic, Ohio.


As of March 2016, 67 subjects have enrolled and 48 have had their whole genomes sequence completed. CReATe aims to enroll 700+ participants overall.